CY1110329T1 - Πεγκυλιωμενη λιποσωμιακη δοξορουβικινη σε συνδυασμο με εκτεϊνασκιδινη 743 - Google Patents

Πεγκυλιωμενη λιποσωμιακη δοξορουβικινη σε συνδυασμο με εκτεϊνασκιδινη 743

Info

Publication number
CY1110329T1
CY1110329T1 CY20091100818T CY091100818T CY1110329T1 CY 1110329 T1 CY1110329 T1 CY 1110329T1 CY 20091100818 T CY20091100818 T CY 20091100818T CY 091100818 T CY091100818 T CY 091100818T CY 1110329 T1 CY1110329 T1 CY 1110329T1
Authority
CY
Cyprus
Prior art keywords
combination
ectein
succinin
pegylated liposomal
liposomal doxorubicin
Prior art date
Application number
CY20091100818T
Other languages
English (en)
Inventor
Erard Gilles
Lars-Axel Sternas
Ovid Trifan
De Velde Helgi Van
April Teitelbaum
Original Assignee
Pharma Mar S.A., Sociedad Unipersonal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36096124&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1110329(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharma Mar S.A., Sociedad Unipersonal filed Critical Pharma Mar S.A., Sociedad Unipersonal
Publication of CY1110329T1 publication Critical patent/CY1110329T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Μέθοδος αγωγής καρκίνου του ανθρώπινου σώματος που αποτελείται από χορήγηση αποτελεσματικής θεραπευτικής ποσότητας μορφή λιποσωμιακής πεγκυλίασης της ανθρακυκίνης Δοξορουβικίνης ("PLD") σε συνδυασμό με αποτελεσματική θεραπευτική ποσότητα ET-743.
CY20091100818T 2004-10-26 2009-08-03 Πεγκυλιωμενη λιποσωμιακη δοξορουβικινη σε συνδυασμο με εκτεϊνασκιδινη 743 CY1110329T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62216304P 2004-10-26 2004-10-26
EP05803151A EP1827500B1 (en) 2004-10-26 2005-10-26 Pegylated liposomal doxorubicin in combination with ecteinescidin 743

Publications (1)

Publication Number Publication Date
CY1110329T1 true CY1110329T1 (el) 2015-01-14

Family

ID=36096124

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100818T CY1110329T1 (el) 2004-10-26 2009-08-03 Πεγκυλιωμενη λιποσωμιακη δοξορουβικινη σε συνδυασμο με εκτεϊνασκιδινη 743

Country Status (27)

Country Link
US (1) US20090117176A1 (el)
EP (1) EP1827500B1 (el)
JP (2) JP4554684B2 (el)
KR (1) KR101287918B1 (el)
CN (1) CN101119750B (el)
AT (1) ATE430586T1 (el)
AU (1) AU2005298364B2 (el)
BR (1) BRPI0518250A2 (el)
CA (1) CA2582452C (el)
CY (1) CY1110329T1 (el)
DE (1) DE602005014380D1 (el)
DK (1) DK1827500T3 (el)
ES (1) ES2326825T3 (el)
HK (1) HK1107766A1 (el)
HR (1) HRP20090345T1 (el)
IL (1) IL182352A (el)
MX (1) MX2007004744A (el)
NO (1) NO328958B1 (el)
NZ (1) NZ554765A (el)
PL (1) PL1827500T3 (el)
PT (1) PT1827500E (el)
RS (1) RS50822B (el)
RU (1) RU2359700C2 (el)
SI (1) SI1827500T1 (el)
UA (1) UA87877C2 (el)
WO (1) WO2006046080A2 (el)
ZA (1) ZA200703396B (el)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
MXPA03003975A (es) * 2000-11-06 2004-02-12 Pharma Mar Sa Composiciones para tratamiento antitumoral, que contienen ecteinascidina 743.
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
PT1689404E (pt) 2003-11-13 2008-12-15 Pharma Mar Sau Combinação de et-743 com pró-fármacos de fluorouracil para o tratamento do cancro
JP2007511509A (ja) * 2003-11-14 2007-05-10 ファルマ・マール・ソシエダード・アノニマ Ｅｔ−７４３およびパクリタキセルの使用を含むガンの併用療法
WO2006046079A1 (en) * 2004-10-29 2006-05-04 Pharma Mar S.A., Sociedad Unipersonal Formulations comprising ecteinascidin and a disaccharide
GB0522082D0 (en) 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
JP5319523B2 (ja) 2006-06-19 2013-10-16 ザ ジョンズ ホプキンス ユニバーシティー リポソマーゼによる治療物質の腫瘍特異的送達
JP2011500046A (ja) * 2007-10-19 2011-01-06 ファルマ・マール・ソシエダード・アノニマ Ｅｔ−７４３治療のための予後分子マーカー
TW201815418A (zh) * 2016-09-27 2018-05-01 Vertex Pharma 使用dna破壞劑及dna-pk抑制劑之組合治療癌症的方法
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
RU2657835C1 (ru) * 2017-11-28 2018-06-15 Федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский технологический университет "МИСиС" Способ получения системы для доставки противоопухолевого препарата в клетки опухоли

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149804A (en) * 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US5256663A (en) * 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5089273A (en) * 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
DE3635711A1 (de) * 1986-10-21 1988-04-28 Knoll Ag 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5478932A (en) * 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US20040059112A1 (en) * 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
GB9508195D0 (en) * 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
US5721362A (en) * 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
US5985876A (en) * 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
PT1067933E (pt) * 1998-04-06 2007-11-15 Univ Illinois Ecteinascidinas semi-sintéticas
US6124292A (en) * 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MY130271A (en) * 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
US20020028237A1 (en) * 2000-04-20 2002-03-07 Colbern Gail T. Method for reducing toxicity of a cytotoxic agent
US7247892B2 (en) * 2000-04-24 2007-07-24 Taylor Geoff W Imaging array utilizing thyristor-based pixel elements
US7420051B2 (en) * 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
CA2418320A1 (en) * 2000-08-11 2002-02-21 City Of Hope The anti-neoplastic agent et-743 inhibits trans activation by sxr
BR0114912A (pt) * 2000-10-31 2003-10-14 Pharma Mar Sa Kahalalide f
MXPA03003975A (es) * 2000-11-06 2004-02-12 Pharma Mar Sa Composiciones para tratamiento antitumoral, que contienen ecteinascidina 743.
CA2439676A1 (en) * 2001-03-06 2002-10-03 Bristol-Myers Squibb Company Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin
US7387790B2 (en) * 2001-06-15 2008-06-17 Cornerstone Pharmaceuticals Pharmaceutical and diagnostic compositions containing nanoparticles useful for treating targeted tissues and cells
PL368458A1 (en) * 2001-10-19 2005-03-21 Pharmamar S.A. Improved use of antitumoral compound in cancer therapy
US20040019027A1 (en) * 2002-04-12 2004-01-29 Barry Forman Method of treating cerebrotendinous xanthomatosis
US20040082856A1 (en) * 2002-07-16 2004-04-29 Alfred E. Mann Institute For Biomedical Engineering, University Of Southern California Support bra for ultrasonic breast scanner
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
PT1689404E (pt) * 2003-11-13 2008-12-15 Pharma Mar Sau Combinação de et-743 com pró-fármacos de fluorouracil para o tratamento do cancro
JP2007511509A (ja) * 2003-11-14 2007-05-10 ファルマ・マール・ソシエダード・アノニマ Ｅｔ−７４３およびパクリタキセルの使用を含むガンの併用療法
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
US20050129752A1 (en) * 2003-12-15 2005-06-16 Tty Biopharm Limited Company Use and manufacturing process for liposomal doxorubicin pharmaceutical composition
NZ552607A (en) * 2004-07-09 2009-07-31 Pharma Mar Sa Prognostic molecular markers
WO2006046079A1 (en) * 2004-10-29 2006-05-04 Pharma Mar S.A., Sociedad Unipersonal Formulations comprising ecteinascidin and a disaccharide
DE602006020335D1 (de) * 2005-11-25 2011-04-07 Pharma Mar Sa Verwendung von parp-1-hemmern
US20080075772A1 (en) * 2006-04-13 2008-03-27 Lawrence Solomon Pharmaceutical compositions having novel scoring patterns and methods of using those compositions
AU2007249281A1 (en) * 2006-05-12 2007-11-22 Pharma Mar, S.A. Anticancer treatments with a combination of docetaxel and ecteinascidin

Also Published As

Publication number Publication date
JP2009292850A (ja) 2009-12-17
NZ554765A (en) 2010-01-29
RS50822B (sr) 2010-08-31
IL182352A0 (en) 2007-07-24
DE602005014380D1 (de) 2009-06-18
RU2359700C2 (ru) 2009-06-27
UA87877C2 (en) 2009-08-25
CN101119750A (zh) 2008-02-06
NO328958B1 (no) 2010-06-28
PT1827500E (pt) 2009-08-05
ATE430586T1 (de) 2009-05-15
KR101287918B1 (ko) 2013-07-19
DK1827500T3 (da) 2009-08-31
WO2006046080A3 (en) 2006-10-19
MX2007004744A (es) 2007-10-23
JP4554684B2 (ja) 2010-09-29
CN101119750B (zh) 2013-03-06
IL182352A (en) 2016-07-31
AU2005298364B2 (en) 2009-03-26
EP1827500B1 (en) 2009-05-06
WO2006046080A8 (en) 2007-07-12
KR20070108135A (ko) 2007-11-08
ES2326825T3 (es) 2009-10-20
HK1107766A1 (en) 2008-04-18
EP1827500A2 (en) 2007-09-05
NO20072543L (no) 2007-07-13
ZA200703396B (en) 2008-11-26
WO2006046080A2 (en) 2006-05-04
AU2005298364A1 (en) 2006-05-04
PL1827500T3 (pl) 2009-09-30
BRPI0518250A2 (pt) 2008-11-11
SI1827500T1 (sl) 2009-10-31
CA2582452A1 (en) 2006-05-04
RU2007119545A (ru) 2008-12-10
CA2582452C (en) 2010-09-07
US20090117176A1 (en) 2009-05-07
HRP20090345T1 (en) 2009-08-31
JP2008517991A (ja) 2008-05-29

Similar Documents

Publication Publication Date Title
CY1110329T1 (el) Πεγκυλιωμενη λιποσωμιακη δοξορουβικινη σε συνδυασμο με εκτεϊνασκιδινη 743
ATE430570T1 (de) Synergistische kombinationstherapie zur krebsbehandlung
FR2869231B1 (fr) Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine
MXPA05012421A (es) Tratamiento sinergistico de cancer usando inmunomeros junto con agentes quimioterapeuticos.
WO2003106659A3 (en) TOXIN-APTAMER MOLECULES AND METHODS OF USE THEREOF
DE60121988D1 (de) Kombinationstherapie mit antidiabetischen und antikonvulsiven mitteln
CY2008007I2 (el) Χρηση του et743 στην συνδυαστικη θεραπεια με δεξαμεθαζονη για την θεραπευτικη αγωγη του καρκινου
DK1401458T3 (da) Sammensætning bestående af PHY906 og kemoterapeutiske midler
PT1244650E (pt) Derivados arilaminas e sua aplicacao como agentes anti-telomerase
NO20032027D0 (no) Effektive antitumorbehandlinger
DE602004023183D1 (de) Gegen antikörper gerichtete photodynamische therapie
MX2007006557A (es) Metodos para utilizar intratecalmente una formulacion de temozolomida en el tratamiento de canceres.
DK1689404T3 (da) Kombination af et-743 med 5-fluoracil-prodrugs til behandling af cancer
MXPA04005207A (es) Metodos para tratar cancer utilizando un inhibidor de la farnesil proteina transferasa y agentes antineoplasticos.
MXPA05009849A (es) Terapia combinada que comprende nemorubicina y un inhibidor de la ciclooxigenasa-2.
BR0308976A (pt) Terapia combinada contra tumores compreendendo derivados de acriloil distamicina substituìda e radioterapia
TR200000728T2 (tr) Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı.
BRPI0409870A (pt) uso de irinotecano para tratamento de cáncer de mama resistente
TW200509922A (en) Methods of therapeutic treatment using amounts of retinoid components
UA36920A (uk) Спосіб лікування хронічного катарального гінгівіту у дітей
TNSN06454A1 (en) Treatment of cancer
MX2007000263A (es) Tratamiento de cancer.
ITMI20001378A0 (it) Uso della nimesulide nel trattamento di patologie dermatologiche
ECSP993003A (es) Uso de peg - ifn -alpha y ribavirina para el tratamiento de hepatitis c cronica